News that Orthocell has been granted a key Canadian patent for our Ortho-ATI product has been published in Small Caps.
Video | CommSec Interview – December 2017
Orthcell CEO and Managing Director, Paul Anderson, speaks with CommSec’s Tom Piotrowski about the company’s two key products, its recently received CE Mark approval for its CelGro™ product and its plans for commercialisation in FY18.
Engineering the future, one intern at a time
What university student would give up their hard-earned summer, leave their friends to vacation on the beach to move to the opposite hemisphere for the coldest weeks of winter to work as an intern? Penn State University biomedical engineering undergraduate student, Margaux Steltz would. And very happily.
Video | AusBiotech Interview – January 2016
Orthocell CEO & Managing Director, Paul Anderson, explains the unique technology behind the company’s cellular regenerative medicine, and in particular how its collagen-based scaffold is different to other collagen therapies.
Orthocell shares surge after getting US patent
Orthocell has been featured in The Australian following news of securing a US patent for our “cell factory” technology.
Orthocell has positive tennis elbow result
Orthocell has been featured in The Australian’s Business Spectator, following the release of new positive results from a study of our tendon cell treatment for tennis elbow.
Funding boost for tendon research
The Australian has featured news of Orthocell’s Australian Research Council grant to continue its tendon research.
Patent success a good sign for Orthocell
Following our recent patent announcement, the Australian Financial Review has featured Orthocell in its Market Wrap.
Strong demand for biotech
The Australian newspaper has featured news of Orthocell’s listing on the ASX.
Biotech Orthocell looks to raise $8m in IPO
Details of Orthocell’s upcoming launch on the ASX has been featured in the Australian Financial Review (AFR).